Furthermore, we indicate a clinical situation where there may be consequences of pharmacological treatment of Parkinson's disease with MAO-B inhibitors in patients with obesity: selegiline may aggravate cardiometabolic diseases and thus increase the patient's susceptibility to cardiac damage. Here, MAOB is linked to obesity disorder.